23,578 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd purchased a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 23,578 shares of the company's stock, valued at approximately $530,000.

Other large investors have also bought and sold shares of the company. Driehaus Capital Management LLC purchased a new position in Nurix Therapeutics during the 2nd quarter worth $26,778,000. Candriam S.C.A. raised its holdings in Nurix Therapeutics by 30.5% during the 2nd quarter. Candriam S.C.A. now owns 1,164,246 shares of the company's stock valued at $24,297,000 after acquiring an additional 272,136 shares during the period. Affinity Asset Advisors LLC lifted its position in shares of Nurix Therapeutics by 12.6% during the second quarter. Affinity Asset Advisors LLC now owns 912,000 shares of the company's stock worth $19,033,000 after acquiring an additional 101,747 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Nurix Therapeutics by 60.2% in the second quarter. Millennium Management LLC now owns 599,623 shares of the company's stock worth $12,514,000 after acquiring an additional 225,374 shares during the period. Finally, Samlyn Capital LLC bought a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at $12,177,000.

Analyst Ratings Changes

NRIX has been the topic of a number of analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $29.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, November 6th. HC Wainwright raised their price target on shares of Nurix Therapeutics from $26.00 to $30.00 and gave the company a "buy" rating in a report on Monday, October 21st. UBS Group began coverage on shares of Nurix Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $35.00 price target on the stock. Oppenheimer lifted their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the company an "outperform" rating in a research note on Wednesday, September 4th. Finally, Stephens restated an "overweight" rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Monday, October 14th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Nurix Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $29.40.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX traded up $0.88 during trading hours on Friday, hitting $22.11. The company's stock had a trading volume of 378,726 shares, compared to its average volume of 902,338. Nurix Therapeutics, Inc. has a 12 month low of $5.95 and a 12 month high of $29.56. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -7.60 and a beta of 2.20. The business has a 50-day simple moving average of $24.02 and a 200-day simple moving average of $21.80.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.67). The firm had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. On average, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.81 EPS for the current year.

Insider Activity at Nurix Therapeutics

In related news, insider Christine Ring sold 5,760 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total value of $128,044.80. Following the completion of the transaction, the insider now directly owns 24,592 shares of the company's stock, valued at $546,680.16. This represents a 18.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Houte Hans Van sold 2,368 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $57,542.40. Following the sale, the chief financial officer now directly owns 37,270 shares in the company, valued at approximately $905,661. The trade was a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,451 shares of company stock worth $663,160 over the last quarter. Corporate insiders own 7.20% of the company's stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.